Site Content
GEN March 2020
Drastic Reduction in COGS using the VHU®
GEN March 2020
GEN March 2020
Drastic Reduction in COGS using the VHU®
GEN March 2020
The VHU® been shown to reduce time of manufacturing by 1/2 and increase viral vector yields by at least an order of magnitude compared to batch processes with suspension cells. By employing the VHU ® in perfusion mode for continuous harvesting of Viral Vectors or Vaccines the Cost of Goods can decrease by as much as 90%.
Drastic Reduction in COGS using the VHU®
Drastic Reduction in COGS using the VHU®
Drastic Reduction in COGS using the VHU®
VHU ® Perfusion for reducing COGS by 90% compared to adherent cell process (eg. CF10)
Leadership
Management Team
Board of Directors
Board of Directors
- Maurizio V. Cattaneo, PhD: Founder and CEO
- Remco A. Spanjaard, PhD: Founder and CSO
Board of Directors
Board of Directors
Board of Directors
- Maurizio V. Cattaneo, PhD: Founder and CEO
- Remco A. Spanjaard, PhD: Founder and CSO
- Jean-Marc Pandraud
- Scott H. Gillis
cost effective viral vector/vaccine manufacturing
The Problem: Cell Factories are inefficient for large scale manufacturing of viral vectors/vaccines
Viral vectors and viral vaccines play an important role in current gene therapy and pandemic vaccine approaches.
Viral vectors like adenoviruses (Ad), or lentiviruses (LV) are the vehicles being developed for delivering genetic material in vaccine prophylaxis and gene therapy. Viral vaccines such as adenovirus to express the SARS-CoV-2 spike protein are the most advanced vaccines to combat the current Covid-19 pandemic. Adenovirus production in perfusion mode can reduce the manufacturing time by 1/2 for obtaining 1 billion doses compared to batch manufacturing.
The Solution: Scalable Production of Viral Vectors using the Viral Harvest Unit ( VHU®)
The use of suspension cells to produce viral vectors/vaccines in perfusion mode offers an alternative solution to batch manufacturing which is gaining traction in the industry. Competing acoustic-based cell retention devices such as BioSep® are limited to R&D production scales. In addition, the current ATF perfusion systems cannot be used for the production of viral vectors because they do not allow the viral vectors (eg. Lentiviral (LV) or Adeno Associated Virus (AAV) to permeate through the hollow fiber membrane (S. Ansorge, et al. Scalable Lentiviral Vector Production using Stable Producer Cell Lines in Perfusion Mode, Poster No. 141, Cell Culture Engineering XVI, May 6-11, 2018).
Artemis Biosystems has developed a scalable production system based on the VHU® (US Patent 10,358,626 B2, Cattaneo and Spanjaard, 2019) to produce clinical or commercial quantities of viral vectors from mammalian cells in suspension culture such as HEK293 or MDCK cells. When using the VHU® in perfusion mode, viral vector/vaccine production is increased by at least 1-2 orders of magnitude (M. Cattaneo, ISBiotech, 9th Spring Meeting on Viral Vectors and Vaccines, Norforlk, VA, 2019). With the help of the VHU® the viral yield is increased by at least an order of magnitude and results in a 50% reduction in the time of manufacturing compared to batch processes.
VHU® PERFUSION System yields 30-Fold viral harvest compared to batch and a 10-fold reduction in the cost of goods compared to cell factories
Images of the VHU® 2
1/2
Contact us if you want to know more about VHU®
Please get in touch by sending us an email at info@artemisbiosystems.com, or call us at 617-674-2747 to discuss how VHU™ can solve your viral vector/vaccine production scale up problems from pilot to commercial scale
Download VHU® Data Sheet
Artemis VHU® System DataSheet_01-2021 (pdf)
DownloadProgress in Viral Vector/vaccine Manufacturing
Suspension cell based VHU® Perfusion for scaling up viral vector manufacturing
- One of he biggest obstacles facing the gene therapy industry is lack of scalable manufacturing of viral vectors. CMOs are currently using legacy adherent cell technology using e.g. cell factories which can be scaled OUT but NOT be scaled up. This causes enormous amounts of technical difficulties and cost to gene therapy companies. The solution: viral vector-producing cells grown in suspension and the VHU® Perfusion system. With the VHU® perfusion system it is possible to scale UP up to 2000L of cell suspension culture in both transient transfection mode and/or stable/inducible producer cell lines which pump out viral vectors in a semi-continuous fashion (Manceur et al. 2017, Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines, Journal of Gene Therapy Methods, Volume 28 Number 6, Pages 330-339).
- For suspension cell lines using transient transfection, the VHU™ Perfusion System is initially used to increase the viable cell density by 1-2 orders of magnitude (1E07-1E08 cells/mL) in a "Process Intensification" mode, after which the cells are transfected with Polyplexes (PEI:DNA complexes) under a batch mode for a few hours to a day, and then the bioreactor is returned to Perfusion mode to harvest the viral vector (such as LV or AAV) in a semi-continuous mode for a few days post transfection (3-5 DPT) (Ansorge et al. 2009, Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cells, The Journal for Gene Medicine, Volume 11, Pages 868-876).
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.